A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors
Tamoxifen and aromatase inhibitors have been used as treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen is a prodrug that is converted by the polymorphic enzyme CYP2D6 into its active form, endoxifen. This month’s Editor’s Choice article examines CYP2D6 genotype and response to tamoxifen compared to the aromatase inhibitors, anastrozole and letrozole in postmenopausal women with estrogen receptor positive breast cancer. The results suggest that in women who get intolerable adverse effects to aromatase inhibitors, if these women are found to be extensive metabolizers for CYP2D6 (as measured by genotyping non-tumor DNA), that the treatment effect of tamoxifen would be comparable to that of aromatase inhibitors.
-- Gwan Cheol Park,MS, Jin-A Jung, PhD, Kyun-Seop Bae, MD, PhD, and Hyeong-Seok Lim, MD, PhD,
- Article Category
- Editor's Choice: Women's Health
A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third‐Generation Aromatase Inhibitors
- First Published:
- | Vol:
- | DOI:
Log in for Access
Log in for access to all ACCP journal content if you are an ACCP member.
to ACCP1.org for access) (Note: you will be redirected
Download the JCP App
iOS App for iPad or iPhone